Stock Performance and Market Context
On 2 March 2026, Beryl Drugs Ltd’s stock recorded an intraday low of Rs.16.2, down nearly 20% from its previous close, despite opening with a modest gain of 2.48%. The stock exhibited high volatility throughout the trading session, with an intraday price range spanning from Rs.16.2 to Rs.20.69, resulting in a weighted average price volatility of 12.14%. This price movement contributed to a day change of -15.85%, underperforming the Pharmaceuticals & Biotechnology sector by 14.89%.
The stock has been on a declining streak for the past two days, losing 21.89% in returns during this period. Notably, trading was absent on one day in the last 20 sessions, indicating sporadic liquidity. Beryl Drugs currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum.
In contrast, the Sensex index, despite opening sharply lower by 2,743.46 points, recovered by 1,387.06 points to close at 79,930.79, down 1.67%. The index remains below its 50-day moving average, although the 50DMA is positioned above the 200DMA, suggesting mixed medium-term market signals.
Long-Term and Recent Financial Performance
Beryl Drugs Ltd’s one-year stock performance has been notably weak, delivering a negative return of 30.51%, while the Sensex gained 9.24% over the same period. The stock’s 52-week high was Rs.30, underscoring the extent of the decline to the current low.
Financially, the company has faced challenges in both top-line and profitability metrics. Net sales for the nine months ended December 2025 stood at Rs.13.84 crores, reflecting a contraction of 20.14% compared to prior periods. Quarterly PBDIT was recorded at a negative Rs.0.20 crores, while PBT excluding other income was at a low of Rs.-0.61 crores. These figures highlight subdued operational results in the near term.
Over the last five years, Beryl Drugs has exhibited modest growth with net sales increasing at an annualised rate of 10.21% and operating profit growing at 5.06%. However, the company’s ability to service debt remains constrained, with an average EBIT to interest coverage ratio of 0.75, indicating limited cushion to meet interest obligations.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Valuation and Comparative Metrics
Despite the recent price decline, Beryl Drugs Ltd’s valuation metrics present a contrasting picture. The company’s return on capital employed (ROCE) stands at 11%, which is considered attractive relative to its sector peers. Additionally, the enterprise value to capital employed ratio is 1.1, suggesting the stock is trading at a discount compared to historical averages within the Pharmaceuticals & Biotechnology sector.
However, the company’s profitability has deteriorated over the past year, with profits declining by 7%. This decline, coupled with the stock’s negative returns, has contributed to a Mojo Score of 31.0 and a Mojo Grade of Sell as of 2 September 2025, an improvement from a previous Strong Sell rating. The market capitalisation grade remains low at 4, reflecting the company’s micro-cap status and limited market presence.
Shareholding and Trading Characteristics
The majority of Beryl Drugs Ltd’s shares are held by non-institutional investors, which may influence trading volumes and price stability. The stock’s erratic trading pattern, including a missed trading day in the recent past, further underscores liquidity concerns. These factors, combined with the stock’s underperformance relative to the BSE500 index over one, three months, and three years, highlight ongoing challenges in market sentiment towards the company.
Considering Beryl Drugs Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Summary of Key Indicators
Beryl Drugs Ltd’s current stock price of Rs.16.2 represents a significant decline from its 52-week high of Rs.30, reflecting a 46% drop over the period. The stock’s recent performance has been marked by high volatility and consistent underperformance relative to sector and market benchmarks. Financial results indicate subdued sales growth and profitability pressures, with limited debt servicing capacity.
Valuation metrics suggest the stock is trading at a discount, supported by a reasonable ROCE and enterprise value to capital employed ratio. Nonetheless, the company’s overall financial health and market positioning remain areas of concern, as reflected in its Mojo Grade of Sell and low market capitalisation rating.
Trading patterns and shareholder composition further contribute to the stock’s price dynamics, with non-institutional majority ownership and occasional erratic trading days.
Conclusion
Beryl Drugs Ltd’s fall to a 52-week low at Rs.16.2 underscores the challenges faced by the company in maintaining growth and profitability within the Pharmaceuticals & Biotechnology sector. The stock’s performance over the past year and recent quarters highlights a cautious environment, with valuation metrics offering some counterbalance to the prevailing negative trends. Market participants continue to monitor the stock’s price action and financial indicators amid a backdrop of sectoral and broader market fluctuations.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
